Home » Newsletters » BioWorld Science

BioWorld Science

July 3, 2014

View Archived Issues

Merz signs agreement with Brickell Biotech for novel retinoid therapy

China's regulatory authority approves phase II trials of F-351

Transcept Pharmaceuticals and Paratek Pharmaceuticals to merge

Pharmacodynamic effects of AZD-3241 revealed in PD patients

Osteogenesis improved in patients with hypophosphatasia

Johnson & Johnson completes divestiture of Ortho-Clinical Diagnostics

FOXO1 as a potential therapeutic target for diabetes demonstrated with AS-1842856

Vertex Pharmaceuticals discloses new ATR inhibitors for cancer

New CB2 receptor agonists patented by Roche

Allergan obtains FDA approval for Ozurdex and updates progress of key programs

Roche designs new SCD inhibitors for cancer

Agenus reports final results from phase II study of Prophage in newly diagnosed GBM

Rigel Pharmaceuticals divulges novel PKC inhibitors for ocular disorders

Researchers in the U.S. and China disclose new agents for cancer and other disorders

Genocea discloses 12-month follow-up data from phase I/IIa trial of HSV vaccine

Boston Strategics forms licensing deal with Eisai for E-6201

Scientists at Pierre Fabre design novel NMDA receptor antagonists

Synageva BioPharma reports topline data from phase III study of sebelipase alfa

Phase I first-in-human study begins for GLPG-1690

Insys Therapeutics receives FDA orphan drug designation for CBD

Genentech to acquire Seragon Pharmaceuticals

Oncoceutics presents preclinical data on lead compound

FDA grants priority review to nintedanib NDA for IPF

Taiho Pharmaceutical seeks additional indication approval in Japan for Zosyn

Rifaximin achieves endpoint in phase III trial in IBS with diarrhea

Boehringer Ingelheim files MAAs for tiotropium/olodaterol combination in Europe

Actavis completes Furiex acquisition

Pozen resubmits aspirin/omeprazole NDAs to the FDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...